Browsing by Yonsei Author : Cho, Byoung Chul

eperson profile image
Name:
Cho, Byoung Chul [조병철]
orcid http://orcid.org/0000-0002-5562-270X
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7401747804)

Keyword Cloud

Researcher Network

Showing results 151 to 200 of 336

This table browses all dspace content
Issue DateTitleJournal Title
2019Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node MetastasisANTICANCER RESEARCH
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE
2019Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing PLOS ONE
2019Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma SCIENTIFIC REPORTS
2019Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 studyLANCET ONCOLOGY
2019High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma SCIENTIFIC REPORTS
2019Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2019Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function JOURNAL FOR IMMUNOTHERAPY OF CANCER
2019Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancerCANCER LETTERS
2019Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trialLANCET ONCOLOGY
2019Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapyLUNG CANCER
2019Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerAnnals of Oncology
2019Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study Journal of Thoracic Oncology
2019Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitorsCancer Chemotherapy and Pharmacology
2019Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection Cancer Research and Treatment
2019NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma Scientific Reports
2019A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIsLung Cancer
2019Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialLancet
2019Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma Cancer Research and Treatment
2019Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2019YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH
2019Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinomaLUNG CANCER
2019Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer YONSEI MEDICAL JOURNAL
2019Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung CancerCLINICAL LUNG CANCER
2019Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate PLOS ONE
2019The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung CancerAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
2019Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetJOURNAL OF THORACIC ONCOLOGY
2019Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunityHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
2019Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer modelsLUNG CANCER
2018Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCNEW ENGLAND JOURNAL OF MEDICINE
2018Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy LUNG CANCER
2018Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in KoreaLUNG CANCER
2018Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptorsNATURE BIOMEDICAL ENGINEERING
2018Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE
2018Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyLANCET ONCOLOGY
2018Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategiesCNACER TREATMENT REVIEWS
2018Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitorsANNALS OF ONCOLOGY
2018Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types CANCER IMMUNOLOGY RESEARCH
2018ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinomaONCOGENE
2018Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical PracticeJOURNAL OF THORACIC ONCOLOGY
2018Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.CANCER RESEARCH
2018Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. LUNG CANCER
2018Can We Prevent Resistance to Osimertinib? Combination or SequentialJOURNAL OF THORACIC ONCOLOGY
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationLUNG CANCER
2018A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal CancerANNALS OF SURGICAL ONCOLOGY
2018Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neckHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
2018Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directionsLUNG CANCER
2017Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer TreatmentBULLETIN OF THE KOREAN CHEMICAL SOCIETY
2017Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry JOURNAL OF CLINICAL ONCOLOGY
2017Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyLANCET RESPIRATORY MEDICINE

Browse

Links